Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 344

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Open access
Ella, Raches, Reddy, Siddarth, Blackwelder, William, Potdar, Varsha, Yadav, Pragya, Sarangi, Vamshi, Aileni, Vinay K, Kanungo, Suman, Rai, Sanjay, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar, Mohapatra, Satyajit, Pandey, Anil, Ranganadin, Pajanivel, Gumashta, Raghavendra, Multani, Manish, Mohammad, Shameem, Bhatt, Parul, Kumari, Laxmi, Sapkal, Gajanan, Gupta, Nivedita, Abraham, Priya, Panda, Samiran, Prasad, Sai, Bhargava, Balram, Ella, Krishna, Vadrevu, Krishna Mohan, Aggarwal, P., Aglawe, V., Ali, A., Anand, N., Awad, N., Bafna, V., Balasubramaniyam, G., Bandkar, A., Basha, P., Bharge, V., Bhate, A., Bhate, S., Bhavani, V., Bhosale, R., Chalapathy, DV, Chaubal, C., Chaudhary, D., Chavan, A., Desai, P., Dhodi, D., Dutta, S., Garg, R., Garg, K., George, M., Goyal, P., Guleria, R., Gupta, S., Jain, M., Jain, M.K., Jindal, S., Kalra, M., Kant, S., Khosla, P., Kulkarni, P., Kumar, P., Kumar, Y., Majumdar, A., Meshram, P., Mishra, V., Mohanty, S., Nair, J., Pandey, S., Panigrahi, S.K., Patil, B., Patil, V., Rahate, P., Raj, V., Ramanand, S., Rami, K., Ramraj, B., Rane, S., Rao, E.V., Rao, N., Raphael, R., Reddy, G., Redkar, V., Redkar, S., Sachdeva, A., Saha, J., Sahoo, J., Sampath, P., Savith, A., Shah, M., Shanmugam, L., Sharma, R., Sharma, P., Sharma, D., Singh, A., Singh, J., Singh, P., Sivaprakasam, S., Subramaniam, S., Sudheer, D., Tandon, S., Tariq, M., Tripathi, V., Vable, M., Verma, R., Waghmare, S.·2021·The Lancet

Abstract

Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults. Methods We did a randomised, double-blind, placebo-controlled, multicentre, phase 3 clinical trial in 25 Indian hospitals or medical clinics to evaluate the efficacy, safety, and immunological lot consistency of BBV152. Adults (age ≥18 years) who were healthy or had stable chronic medical conditions (not an immunocompromising condition or requiring treatment with immunosuppressive therapy) were randomised 1:1 with a computer-generated randomisation scheme (stratified for the presence or absence of chronic conditions) to receive two intramuscular doses of vaccine or placebo administered 4 weeks apart. Participants, investigators, study coordinators, study-related personnel, the sponsor, and nurses who administered the vaccines were masked to treatment group allocation; an unmasked contract research organisation and a masked expert adjudication panel assessed outcomes. The primary outcome was the efficacy of the BBV152 vaccine in preventing a first occurrence of laboratory-confirmed (RT-PCR-positive) symptomatic COVID-19 (any severity), occurring at least 14 days after the second dose in the per-protocol population. We also assessed safety and reactogenicity throughout the duration of the study in all participants who had received at least one dose of vaccine or placebo. This report contains interim results (data cutoff May 17, 2021) regarding immunogenicity and safety outcomes (captured on days 0 to 56) and efficacy results with a median of 99 days for the study population. The trial was registered on the Indian Clinical Trials Registry India, CTRI/2020/11/028976, and ClinicalTrials.gov, NCT04641481 (active, not recruiting). Findings Between Nov 16, 2020, and Jan 7, 2021, we recruited 25 798 participants who were randomly assigned to receive BBV152 or placebo; 24 419 received two doses of BBV152 (n=12 221) or placebo (n=12 198). Efficacy analysis was dependent on having 130 cases of symptomatic COVID-19, which occurred when 16 973 initially seronegative participants had at least 14 days follow-up after the second dose. 24 (0·3%) cases occurred among 8471 vaccine recipients and 106 (1·2%) among 8502 placebo recipients, giving an overall estimated vaccine efficacy of 77·8% (95% CI 65·2–86·4). In the safety population (n=25 753), 5959 adverse events occurred in 3194 participants. BBV152 was well tolerated; the same proportion of participants reported adverse events in the vaccine group (1597 [12·4%] of 12 879) and placebo group (1597 [12·4%] of 12 874), with no clinically significant differences in the distributions of solicited, unsolicited, or serious adverse events between the groups, and no cases of anaphylaxis or vaccine-related deaths. Interpretation BBV152 was highly efficacious against laboratory-confirmed symptomatic COVID-19 disease in adults. Vaccination was well tolerated with no safety concerns raised in this interim analysis. Funding Bharat Biotech International and Indian Council of Medical Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02000-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Choudhary, 2020, Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India, Indian J Med Res, 151, 251, 10.4103/ijmr.IJMR_671_20 · doi:10.4103/ijmr.ijmr_671_20

Cited by

See all 344

Metadata

Authors
Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P., Sarangi, V., Aileni, V. K., Kanungo, S., Rai, S., Reddy, P., Verma, S., Singh, C., Redkar, S., Mohapatra, S., Pandey, A., Ranganadin, P., Gumashta, R., Multani, M., Mohammad, S., Bhatt, P., Kumari, L., Sapkal, G., Gupta, N., Abraham, P., Panda, S., Prasad, S., Bhargava, B., Ella, K., Vadrevu, K. M., Aggarwal, P., Aglawe, V., Ali, A., Anand, N., Awad, N., Bafna, V., Balasubramaniyam, G., Bandkar, A., Basha, P., Bharge, V., Bhate, A., Bhate, S., Bhavani, V., Bhosale, R., Chalapathy, D., Chaubal, C., Chaudhary, D., Chavan, A., Desai, P., Dhodi, D., Dutta, S., Garg, R., Garg, K., George, M., Goyal, P., Guleria, R., Gupta, S., Jain, M., Jain, M. K., Jindal, S., Kalra, M., Kant, S., Khosla, P., Kulkarni, P., Kumar, P., Kumar, Y., Majumdar, A., Meshram, P., Mishra, V., Mohanty, S., Nair, J., Pandey, S., Panigrahi, S. K., Patil, B., Patil, V., Rahate, P., Raj, V., Ramanand, S., Rami, K., Ramraj, B., Rane, S., Rao, E. V., Rao, N., Raphael, R., Reddy, G., Redkar, V., Redkar, S., Sachdeva, A., Saha, J., Sahoo, J., Sampath, P., Savith, A., Shah, M., Shanmugam, L., Sharma, R., Sharma, P., Sharma, D., Singh, A., Singh, J., Singh, P., Sivaprakasam, S., Subramaniam, S., Sudheer, D., Tandon, S., Tariq, M., Tripathi, V., Vable, M., Verma, R., & Waghmare, S.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-12
Volume
398
Issue
10317
Pages
2173-2184
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3211505703
Cited by
344
References
26
FWCI
22.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02000-6
The paper
Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P., Sarangi, V., Aileni, V. K., Kanungo, S., Rai, S., Reddy, P., Verma, S., Singh, C., Redkar, S., Mohapatra, S., Pandey, A., Ranganadin, P., Gumashta, R., Multani, M., Mohammad, S., . . . Waghmare, S. (2021). Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)02000-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.